Source: Onconova Therapeutics, Inc. 1/2/19
- SPA submitted to the FDA before year-end 2018, marking achievement of a key regulatory milestone
- Advancement of this Phase 3 program, in treatment-naïve higher risk first-line MDS patients, positions rigosertib in an expanded patient population with a more convenient mode of administration
- 2019 focus remains on the completion of the pivotal INSPIRE trial studying intravenous rigosertib in second-line higher-risk MDS, while advancing business development connected to the progress of both oral and intravenous rigosertib
Onconova Therapeutics, Inc. (NASDAQ:ONTX),
a Phase 3-stage biopharmaceutical company focused on discovering and
developing novel products to treat cancer, with a primary focus on MDS,
today announced that it has submitted a Special Protocol Assessment
request to the U.S. Food and Drug Administration (FDA) for a Phase 3
study of oral rigosertib combination therapy with azacitidine (Vidaza®)
for the treatment of adult patients with treatment-naïve higher-risk
MDS. The request is part of the Company’s ongoing interaction with the
FDA, following an End-of-Phase 2 Meeting with FDA guidance for the
proposed Phase 3 study and Scientific Advice from the European Health
Authorities, consistent with the Company’s strategy to study rigosertib
in an earlier higher-risk MDS patient population with a more convenient
mode of oral rigosertib administration. The End-of-Phase 2 Meeting also
outlined that the primary endpoint of the proposed pivotal trial will
be overall response rate (ORR), a composite of complete remission (CR),
and partial remission (PR) based on the IWG Response Criteria.
Dr.
Steve Fruchtman, President of Onconova, commented: “We remain focused
in 2019 on the completion of the pivotal INSPIRE trial studying
intravenous rigosertib in higher-risk MDS after patients fail to respond
to or progress on hypomethylation therapy, the standard of care. The
timely achievement of this regulatory milestone of this SPA submission
is an important step in advancing the development of rigosertib for
patients with earlier stage higher-risk MDS. We believe that the
promising data in hand, including the data from the Phase 2 expansion
trial of oral rigosertib and azacitidine presented at this year’s 2018
ASH Annual Meeting, provides a strong scientific rationale for the
proposed Phase 3 program. As the INSPIRE trial continues to mature, we
look forward to a constructive engagement with the FDA on future
studies. We also aim to help fund these additional studies through
expanding our partnerships.”
The FDA’s SPA
process fosters dialogue between the FDA and clinical trial sponsors
before studies commence, in an attempt to reach potential agreement with
the agency on the design and size of clinical trials, to determine if
they adequately address the scientific and regulatory requirements for a
study to ultimately support marketing approval. The Company expects its
dialogue with the FDA on this SPA submission to conclude in H1 2019.
About Onconova Therapeutics, Inc.
Onconova
Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused
on discovering and developing novel small molecule drug candidates to
treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).
Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small
molecule agent, which the Company believes blocks cellular signaling by
targeting RAS effector pathways. Using a proprietary chemistry
platform, Onconova has created a pipeline of targeted agents designed to
work against specific cellular pathways that are important in cancer
cells. Onconova has three product candidates in the clinical stage and
several pre-clinical programs. Advanced clinical trials with the
Company’s lead compound, Rigosertib, are aimed at what the Company
believes are unmet medical needs of patients with MDS. For more
information, please visit http://www.onconova.com.
About IV Rigosertib
Intravenous
rigosertib has been employed in Phase 1, 2, and 3 clinical trials
involving more than 800 patients, and is currently being evaluated in a
randomized Phase 3 international INSPIRE trial for patients with
higher-risk MDS, after failure of hypomethylating agent, or HMA,
therapy.
About INSPIRE
The INternational Study of Phase III IV RigosErtib, or INSPIRE,
was finalized following guidance received from the U.S. Food and Drug
Administration and European Medicines Agency and derives from the
findings of the ONTIME Phase 3 trial. INSPIRE is a multi-center,
randomized controlled study to assess the efficacy and safety of IV
rigosertib in Higher Risk-MDS patients who had progressed on, failed to
respond to, or relapsed after previous treatment with an HMA within the
first 9 months or nine cycles over the course of one year after
initiation of HMA treatment. This time frame optimizes the opportunity
to respond to treatment with an HMA prior to declaring treatment
failure, as per NCCN Guidelines. Following interim analysis in early
2018, the independent Data Monitoring Committee recommended that the
trial continue with an expansion in enrollment to 360 patients based on a
pre-planned sample size re-estimation. Patients are randomized at a
2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care
versus Physician's Choice plus Best Supportive Care. The primary
endpoint of INSPIRE is overall survival. Full details of the INSPIRE
trial, such as inclusion and exclusion criteria, as well as secondary
endpoints, can be found on clinicaltrials.gov (NCT02562443).
About Oral Rigosertib
The
oral form of rigosertib was developed to provide more convenient dosing
for use where the duration of treatment may extend to multiple years.
This dosage form may also support combination therapy modalities. To
date, more than 400 patients have been treated with the oral formulation
of rigosertib. Initial studies with single-agent oral rigosertib were
conducted in hematological malignancies, lower-risk MDS, and solid
tumors. Combination therapy of oral rigosertib with azacitidine,
chemotherapy or radiotherapy has also been explored. Currently, oral
rigosertib is being developed as a combination therapy together with
azacitidine for patients with higher-risk MDS who require HMA therapy.
The results of an expanded Phase 2 trial of oral rigosertib combination
therapy with azacitidine were presented at the 2018 ASH Annual Meeting.
This novel combination is the subject of an issued U.S. patent with
earliest expiration in 2028. Additional patents covering oral and
injectable rigosertib have been issued in the US, and are expected to
provide coverage until at least 2037.
No comments:
Post a Comment